Anti-angiogenic activity of chloride and potassium channel modulators: repurposing ion channel modulators
Authors:
Open Access
- 22 June 2020
- journal article
- research article
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 6 (1) , 1-8
Abstract
Background: Excessive angiogenesis can be the root cause of many pathological conditions. Various types of ion channels are found on the endothelial cells. These ion channels play a vital role in the multi-stepped process of angiogenesis. The study aims to investigate the anti-angiogenic effects of specific ion channel modulators mefloquine (volume-regulated chloride channel blocker), lubiprostone (ClC-2 channel agonist), and 4-aminopyridine (voltage-gated potassium channel blocker). Results: The anti-angiogenic activity of ion channel modulators was screened by measuring its effects on the area of neovascularization and histopathological studies by in vivo (corneal neovascularization) method and by in vitro assays, endothelial cell proliferation assay, cell migration assay, and matrigel cord-like morphogenesis assay. The test and standard drug (bevacizumab) groups were compared with the control group using one-way ANOVA, followed by post hoc test, and Dunnett’s test to compare the mean of all the groups with the control mean. The results revealed that mefloquine at the dose of 0.6% w/v and 1.0% w/v, lubiprostone at the dose of 0.5% w/v and 1.0% w/v, and 4-aminopyridine at the dose of 2% w/v and 4% w/v showed significant anti-angiogenic property. In the studies on human umbilical vein endothelial cells, the test drugs (100 nM) showed significant inhibition of proliferation, migration, and decrease in network length of cord-like tubes. Conclusion: The scientific findings indicate that the test drugs have potent anti-angiogenic activity by inhibiting the cell proliferation, inhibiting the cell volume increase, arresting the cell cycle progression and by causing membrane hyperpolarization. The potent anti-angiogenic drugs obtained by repurposing these ion channel modulators, in the further studies, will be able to treat the diseases due to excess angiogenesis from the root cause. GraphicalKeywords
Funding Information
- UGC,Minor research grant, 2016 (ROMRP-SERO-PHAR-2015-16-68663)
This publication has 32 references indexed in Scilit:
- Broad targeting of angiogenesis for cancer prevention and therapySeminars in Cancer Biology, 2015
- Systems biology of ion channels and transporters in tumor angiogenesis: An omics viewBiochimica et Biophysica Acta (BBA) - Biomembranes, 2015
- Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculatureMatrix Biology, 2015
- Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and BeyondJournal of Cancer Research, 2013
- Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibitionJournal of Diabetes and its Complications, 2012
- In vitro and in vivo evaluation of the anti‐angiogenic actions of 4‐hydroxybenzyl alcoholBritish Journal of Pharmacology, 2011
- AngiogenesisColloquium Series on Integrated Systems Physiology: From Molecule to Function, 2010
- New Trends in Cancer Therapy: Targeting Ion Channels and TransportersPharmaceuticals, 2010
- Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseasesNature Reviews Drug Discovery, 2010
- Ion Channels and Their Functional Role in Vascular EndotheliumPhysiological Reviews, 2001